Search

Your search keyword '"Demir, Münevver"' showing total 22 results

Search Constraints

Start Over You searched for: Author "Demir, Münevver" Remove constraint Author: "Demir, Münevver" Publisher elsevier bv Remove constraint Publisher: elsevier bv
22 results on '"Demir, Münevver"'

Search Results

1. TOP-003-YI Model for end-stage liver disease score-based liver allocation is associated with reduced survival in low donation countries-a comparative analysis between Germany and the USA

2. Soluble urokinase plasminogen activator receptor levels predict survival in patients with portal hypertension undergoing TIPS

3. A global research priority agenda to advance public health responses to fatty liver disease

4. Improvements in ALT levels during Bulevirtide treatment for hepatitis D are seen regardless of virologic response

6. Soluble urokinase plasminogen activator receptor is a biomarker for outcome in decompensated liver cirrhosis and acute-on-chronic liver failure

7. Cenicriviroc for the treatment of COVID-19: first interim results of a randomised, placebo-controlled, investigator-initiated, double-blind phase II trial

8. Treating hepatitis D with bulevirtide – Real-world experience from 114 patients

10. Dietary omega-6/omega-3 ratio is not associated with gut microbiota composition and disease severity in patients with nonalcoholic fatty liver disease

11. Bulevirtide treatment of hepatitis D in Germany: multicentre real-world experience

13. The fecal mycobiome in non-alcoholic fatty liver disease

14. Complement activation induces excessive T cell cytotoxicity in severe COVID-19

16. Complement Activation Induces Excessive T Cell Cytotoxicity in Severe COVID-19

17. Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease

18. Prediction of advanced fibrosis with transient elastography is superior to gut microbiota-based approaches in non-alcoholic fatty liver disease

19. Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial

20. Su1084 – No Significant Impact of Fructose Consumption on Gut Microbiota Composition in a German Cohort of Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease (NAFLD)

21. FRI-268-Microbiota signature differs significantly between NAFLD and healthy controls but not between NAFL and NASH

Catalog

Books, media, physical & digital resources